Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBevantolol
Identification
- Name
- Bevantolol
- Accession Number
- DB01295
- Type
- Small Molecule
- Groups
- Approved
- Description
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
- Structure
Structure for DB01295 (Bevantolol)
- Synonyms
- (+-)-Bevantolol
- 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
- 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol
- 1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol
- 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol
- Bevantololum
- Categories
- Adrenergic Agents
- Adrenergic Antagonists
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-Antagonists
- Alcohols
- Alpha1 Antagonists
- Amines
- Amino Alcohols
- Beta Blocking Agents
- Beta Blocking Agents and Thiazides
- Beta Blocking Agents, Selective, and Thiazides
- Cardiovascular System
- Neurotransmitter Agents
- Propanols
- UNII
- 34ZXW6ZV21
- CAS number
- 59170-23-9
- Weight
- Average: 345.4327
Monoisotopic: 345.194008357 - Chemical Formula
- C20H27NO4
- InChI Key
- HXLAFSUPPDYFEO-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
- IUPAC Name
- 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
- SMILES
- COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1
Pharmacology
- Indication
For the treatment of angina pectoris and hypertension.
- Structured Indications
- Not Available
- Pharmacodynamics
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
- Mechanism of action
Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.
Target Actions Organism ABeta-1 adrenergic receptor antagonistHuman UBeta-2 adrenergic receptor antagonistHuman UAlpha-1A adrenergic receptor antagonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Bevantolol Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may decrease the antihypertensive activities of Bevantolol. Investigational 1,10-Phenanthroline 1,10-Phenanthroline may increase the bradycardic activities of Bevantolol. Experimental 4-Methoxyamphetamine 4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Experimental, Illicit Aceclofenac Aceclofenac may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Acemetacin Acemetacin may decrease the antihypertensive activities of Bevantolol. Approved, Experimental, Investigational Acepromazine Acepromazine may increase the hypotensive activities of Bevantolol. Approved, Vet Approved Aceprometazine Aceprometazine may increase the hypotensive activities of Bevantolol. Approved Acetohexamide Bevantolol may increase the hypoglycemic activities of Acetohexamide. Approved, Investigational, Withdrawn Acetylcholine The risk or severity of adverse effects can be increased when Bevantolol is combined with Acetylcholine. Approved Acetyldigitoxin Bevantolol may increase the bradycardic activities of Acetyldigitoxin. Approved Acetyldigoxin Bevantolol may increase the bradycardic activities of Acetyldigoxin. Experimental Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Adapalene Adapalene may decrease the antihypertensive activities of Bevantolol. Approved Agmatine Agmatine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Experimental, Investigational Alaproclate The serum concentration of Bevantolol can be increased when it is combined with Alaproclate. Experimental Alclofenac Alclofenac may decrease the antihypertensive activities of Bevantolol. Approved, Withdrawn Alfentanil Alfentanil may increase the bradycardic activities of Bevantolol. Approved, Illicit Alfuzosin Bevantolol may increase the orthostatic hypotensive activities of Alfuzosin. Approved, Investigational Alimemazine Alimemazine may increase the hypotensive activities of Bevantolol. Approved, Vet Approved Alminoprofen Alminoprofen may decrease the antihypertensive activities of Bevantolol. Experimental Ambenonium Ambenonium may increase the bradycardic activities of Bevantolol. Approved Amiodarone The therapeutic efficacy of Bevantolol can be increased when used in combination with Amiodarone. Approved, Investigational Amobarbital The serum concentration of Bevantolol can be decreased when it is combined with Amobarbital. Approved, Illicit Amodiaquine The metabolism of Bevantolol can be decreased when combined with Amodiaquine. Approved, Investigational Andrographolide Andrographolide may decrease the antihypertensive activities of Bevantolol. Investigational Anisodamine Anisodamine may decrease the antihypertensive activities of Bevantolol. Investigational Antipyrine Antipyrine may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Apocynin Apocynin may decrease the antihypertensive activities of Bevantolol. Investigational Apomorphine Apomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Apremilast Apremilast may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Arecoline The risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline. Experimental Azapropazone Azapropazone may decrease the antihypertensive activities of Bevantolol. Withdrawn Azelastine Azelastine may decrease the antihypertensive activities of Bevantolol. Approved Balsalazide Balsalazide may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Barbexaclone The serum concentration of Bevantolol can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Bevantolol can be decreased when it is combined with Barbital. Illicit Bendazac Bendazac may decrease the antihypertensive activities of Bevantolol. Experimental Benorilate Benorilate may decrease the antihypertensive activities of Bevantolol. Experimental Benoxaprofen Benoxaprofen may decrease the antihypertensive activities of Bevantolol. Withdrawn Benzphetamine Benzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Illicit Benzydamine Benzydamine may decrease the antihypertensive activities of Bevantolol. Approved Bethanechol The risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol. Approved Bethanidine Bethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Bevonium Bevonium may decrease the antihypertensive activities of Bevantolol. Experimental BL-1020 BL-1020 may increase the hypotensive activities of Bevantolol. Investigational Brimonidine Brimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Bromfenac Bromfenac may decrease the antihypertensive activities of Bevantolol. Approved Bromocriptine Bromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Bucillamine Bucillamine may decrease the antihypertensive activities of Bevantolol. Investigational Bucindolol Bevantolol may increase the orthostatic hypotensive activities of Bucindolol. Investigational Bufexamac Bufexamac may decrease the antihypertensive activities of Bevantolol. Approved, Experimental Bumadizone Bumadizone may decrease the antihypertensive activities of Bevantolol. Experimental Bunazosin Bevantolol may increase the orthostatic hypotensive activities of Bunazosin. Investigational Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Bevantolol. Approved, Investigational Cabergoline Bevantolol may increase the vasoconstricting activities of Cabergoline. Approved Carbachol The risk or severity of adverse effects can be increased when Bevantolol is combined with Carbachol. Approved Carbaspirin calcium Carbaspirin calcium may decrease the antihypertensive activities of Bevantolol. Experimental, Investigational Carbutamide Bevantolol may increase the hypoglycemic activities of Carbutamide. Experimental Carprofen Carprofen may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved, Withdrawn Carvedilol Bevantolol may increase the orthostatic hypotensive activities of Carvedilol. Approved, Investigational Castanospermine Castanospermine may decrease the antihypertensive activities of Bevantolol. Experimental Celecoxib Celecoxib may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Cevimeline The risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline. Approved Chloroquine The metabolism of Bevantolol can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorproethazine Chlorproethazine may increase the hypotensive activities of Bevantolol. Experimental Chlorpromazine Chlorpromazine may increase the hypotensive activities of Bevantolol. Approved, Investigational, Vet Approved Chlorpropamide Bevantolol may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the antihypertensive activities of Bevantolol. Approved Clonidine Clonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Clonixin Clonixin may decrease the antihypertensive activities of Bevantolol. Approved Coumaphos Coumaphos may increase the bradycardic activities of Bevantolol. Vet Approved Curcumin Curcumin may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Cymarin Bevantolol may increase the bradycardic activities of Cymarin. Experimental Dapoxetine The serum concentration of Bevantolol can be increased when it is combined with Dapoxetine. Investigational Decamethonium Decamethonium may increase the bradycardic activities of Bevantolol. Approved Demecarium Demecarium may increase the bradycardic activities of Bevantolol. Approved Deslanoside Bevantolol may increase the bradycardic activities of Deslanoside. Approved Desvenlafaxine The serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine. Approved, Investigational Dexmedetomidine Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Vet Approved Dichlorvos Dichlorvos may increase the bradycardic activities of Bevantolol. Vet Approved Diclofenac Diclofenac may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Difenpiramide Difenpiramide may decrease the antihypertensive activities of Bevantolol. Experimental Diflunisal Diflunisal may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Digitoxin Bevantolol may increase the bradycardic activities of Digitoxin. Approved, Investigational Digoxin Bevantolol may increase the bradycardic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Bevantolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine). Approved Dihydroergotamine Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Diltiazem Diltiazem may increase the hypotensive activities of Bevantolol. Approved, Investigational Dipivefrin Dipivefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Dipyridamole Dipyridamole may increase the bradycardic activities of Bevantolol. Approved Disopyramide Disopyramide may increase the bradycardic activities of Bevantolol. Approved Distigmine Distigmine may increase the bradycardic activities of Bevantolol. Experimental Donepezil Donepezil may increase the bradycardic activities of Bevantolol. Approved Doxazosin Bevantolol may increase the orthostatic hypotensive activities of Doxazosin. Approved Dronedarone Dronedarone may increase the bradycardic activities of Bevantolol. Approved Droxicam Droxicam may decrease the antihypertensive activities of Bevantolol. Withdrawn Droxidopa Droxidopa may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Duloxetine The serum concentration of Bevantolol can be increased when it is combined with Duloxetine. Approved Duvelisib Duvelisib may decrease the antihypertensive activities of Bevantolol. Investigational E-6201 E-6201 may decrease the antihypertensive activities of Bevantolol. Investigational Echothiophate Echothiophate may increase the bradycardic activities of Bevantolol. Approved Edrophonium Edrophonium may increase the bradycardic activities of Bevantolol. Approved Ephedra Ephedra may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Nutraceutical, Withdrawn Epibatidine The risk or severity of adverse effects can be increased when Bevantolol is combined with Epibatidine. Experimental Epinephrine Epinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Vet Approved Epirizole Epirizole may decrease the antihypertensive activities of Bevantolol. Approved Ergoloid mesylate Bevantolol may increase the vasoconstricting activities of Ergoloid mesylate. Approved Ergonovine Bevantolol may increase the vasoconstricting activities of Ergonovine. Approved Ergotamine Ergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Etanercept Etanercept may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Ethenzamide Ethenzamide may decrease the antihypertensive activities of Bevantolol. Experimental Etodolac Etodolac may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Vet Approved Etofenamate Etofenamate may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Etomidate Etomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Etoperidone The serum concentration of Bevantolol can be increased when it is combined with Etoperidone. Withdrawn Etoricoxib Etoricoxib may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Evening primrose oil Evening primrose oil may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Exisulind Exisulind may decrease the antihypertensive activities of Bevantolol. Investigational Felbinac Felbinac may decrease the antihypertensive activities of Bevantolol. Experimental Fenbufen Fenbufen may decrease the antihypertensive activities of Bevantolol. Approved Fenoprofen Fenoprofen may decrease the antihypertensive activities of Bevantolol. Approved Fentanyl Fentanyl may increase the bradycardic activities of Bevantolol. Approved, Illicit, Investigational, Vet Approved Fenthion Fenthion may increase the bradycardic activities of Bevantolol. Vet Approved Fentiazac Fentiazac may decrease the antihypertensive activities of Bevantolol. Experimental Feprazone Feprazone may decrease the antihypertensive activities of Bevantolol. Experimental Ferulic acid Ferulic acid may decrease the antihypertensive activities of Bevantolol. Experimental Fingolimod Bevantolol may increase the bradycardic activities of Fingolimod. Approved, Investigational Floctafenine The risk or severity of adverse effects can be increased when Bevantolol is combined with Floctafenine. Approved, Withdrawn Flunixin Flunixin may decrease the antihypertensive activities of Bevantolol. Vet Approved Flunoxaprofen Flunoxaprofen may decrease the antihypertensive activities of Bevantolol. Experimental Fluoxetine The serum concentration of Bevantolol can be increased when it is combined with Fluoxetine. Approved, Vet Approved Fluphenazine Fluphenazine may increase the hypotensive activities of Bevantolol. Approved Flurbiprofen Flurbiprofen may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Galantamine Galantamine may increase the bradycardic activities of Bevantolol. Approved Gallamine Triethiodide Gallamine Triethiodide may increase the bradycardic activities of Bevantolol. Approved Gitoformate Bevantolol may increase the bradycardic activities of Gitoformate. Experimental Glibornuride Bevantolol may increase the hypoglycemic activities of Glibornuride. Investigational, Withdrawn Gliclazide Bevantolol may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Bevantolol may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Bevantolol may increase the hypoglycemic activities of Glipizide. Approved, Investigational Gliquidone Bevantolol may increase the hypoglycemic activities of Gliquidone. Approved, Investigational Glisoxepide Bevantolol may increase the hypoglycemic activities of Glisoxepide. Investigational Glyburide Bevantolol may increase the hypoglycemic activities of Glyburide. Approved GTS-21 The risk or severity of adverse effects can be increased when Bevantolol is combined with GTS-21. Investigational Guacetisal Guacetisal may decrease the antihypertensive activities of Bevantolol. Experimental Guanabenz Guanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Guanfacine Guanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Hexobarbital The serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital. Approved Higenamine Higenamine may decrease the antihypertensive activities of Bevantolol. Investigational Huperzine A Huperzine A may increase the bradycardic activities of Bevantolol. Approved, Investigational Hydroxychloroquine The metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine. Approved Ibuprofen Ibuprofen may decrease the antihypertensive activities of Bevantolol. Approved Ibuproxam Ibuproxam may decrease the antihypertensive activities of Bevantolol. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Imidazole salicylate Imidazole salicylate may decrease the antihypertensive activities of Bevantolol. Experimental Indalpine The serum concentration of Bevantolol can be increased when it is combined with Indalpine. Investigational, Withdrawn Indobufen Indobufen may decrease the antihypertensive activities of Bevantolol. Investigational Indomethacin Indomethacin may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Indoprofen Indoprofen may decrease the antihypertensive activities of Bevantolol. Withdrawn Indoramin Bevantolol may increase the orthostatic hypotensive activities of Indoramin. Withdrawn Insulin Human Bevantolol may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Pork Bevantolol may increase the hypoglycemic activities of Insulin Pork. Approved Ipidacrine Ipidacrine may increase the bradycardic activities of Bevantolol. Experimental Isoflurophate Isoflurophate may increase the bradycardic activities of Bevantolol. Approved, Investigational, Withdrawn Isoxicam Isoxicam may decrease the antihypertensive activities of Bevantolol. Withdrawn Kebuzone Kebuzone may decrease the antihypertensive activities of Bevantolol. Experimental Ketoprofen Ketoprofen may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Ketorolac Ketorolac may decrease the antihypertensive activities of Bevantolol. Approved Labetalol Bevantolol may increase the orthostatic hypotensive activities of Labetalol. Approved Lanatoside C Bevantolol may increase the bradycardic activities of Lanatoside C. Experimental Leflunomide Leflunomide may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Levomilnacipran The serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran. Approved, Investigational Levonordefrin Levonordefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Bevantolol. Approved, Vet Approved Lisofylline Lisofylline may decrease the antihypertensive activities of Bevantolol. Investigational Lobeline The risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline. Investigational Lofexidine Lofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Lonazolac Lonazolac may decrease the antihypertensive activities of Bevantolol. Experimental Lornoxicam Lornoxicam may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Loxoprofen Loxoprofen may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Lumiracoxib Lumiracoxib may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Magnesium salicylate Magnesium salicylate may decrease the antihypertensive activities of Bevantolol. Approved Malathion Malathion may increase the bradycardic activities of Bevantolol. Approved, Investigational Masoprocol Masoprocol may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Meclofenamic acid Meclofenamic acid may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Mefenamic acid Mefenamic acid may decrease the antihypertensive activities of Bevantolol. Approved Mefloquine Mefloquine may increase the bradycardic activities of Bevantolol. Approved, Investigational Meloxicam Meloxicam may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Memantine Memantine may increase the bradycardic activities of Bevantolol. Approved, Investigational Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Bevantolol. Approved, Vet Approved Mesalazine Mesalazine may decrease the antihypertensive activities of Bevantolol. Approved Mesoridazine Mesoridazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Metahexamide Bevantolol may increase the hypoglycemic activities of Metahexamide. Experimental Metamizole Metamizole may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Withdrawn Methacholine Bevantolol may increase the bronchoconstrictory activities of Methacholine. Approved, Investigational Methamphetamine Methamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Illicit Methanesulfonyl Fluoride Methanesulfonyl Fluoride may increase the bradycardic activities of Bevantolol. Investigational Methohexital The serum concentration of Bevantolol can be decreased when it is combined with Methohexital. Approved Methotrimeprazine Methotrimeprazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Methylene blue Methylene blue may increase the hypotensive activities of Bevantolol. Approved, Investigational Methylergometrine Bevantolol may increase the vasoconstricting activities of Methylergometrine. Approved Methylphenobarbital The serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital. Approved Metildigoxin Bevantolol may increase the bradycardic activities of Metildigoxin. Experimental Metoclopramide Metoclopramide may increase the bradycardic activities of Bevantolol. Approved, Investigational Midodrine Bevantolol may increase the bradycardic activities of Midodrine. Approved Milnacipran The serum concentration of Bevantolol can be increased when it is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the bradycardic activities of Bevantolol. Approved Mizoribine Mizoribine may decrease the antihypertensive activities of Bevantolol. Investigational Mofebutazone Mofebutazone may decrease the antihypertensive activities of Bevantolol. Experimental Moricizine Moricizine may increase the hypotensive activities of Bevantolol. Approved, Investigational, Withdrawn Moxonidine Moxonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Mycophenolic acid Mycophenolic acid may decrease the antihypertensive activities of Bevantolol. Approved Nabumetone Nabumetone may decrease the antihypertensive activities of Bevantolol. Approved Nafamostat Nafamostat may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Naftifine Naftifine may decrease the antihypertensive activities of Bevantolol. Approved Naphazoline Naphazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Naproxen Naproxen may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Nefazodone The serum concentration of Bevantolol can be increased when it is combined with Nefazodone. Approved, Withdrawn Neostigmine Neostigmine may increase the bradycardic activities of Bevantolol. Approved, Vet Approved Nepafenac Nepafenac may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Nicotine The risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine. Approved Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bevantolol. Approved Nifenazone Nifenazone may decrease the antihypertensive activities of Bevantolol. Experimental Niflumic Acid Niflumic Acid may decrease the antihypertensive activities of Bevantolol. Approved Nimesulide Nimesulide may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Withdrawn Nitroaspirin Nitroaspirin may decrease the antihypertensive activities of Bevantolol. Investigational Norepinephrine Norepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Oleandrin Bevantolol may increase the bradycardic activities of Oleandrin. Experimental, Investigational Olopatadine Olopatadine may decrease the antihypertensive activities of Bevantolol. Approved Olsalazine Olsalazine may decrease the antihypertensive activities of Bevantolol. Approved Orgotein Orgotein may decrease the antihypertensive activities of Bevantolol. Vet Approved Ouabain Bevantolol may increase the bradycardic activities of Ouabain. Approved Oxaprozin Oxaprozin may decrease the antihypertensive activities of Bevantolol. Approved Oxymetazoline Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Oxyphenbutazone Oxyphenbutazone may decrease the antihypertensive activities of Bevantolol. Approved, Withdrawn Paliperidone Paliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Paraoxon Paraoxon may increase the bradycardic activities of Bevantolol. Experimental Parecoxib Parecoxib may decrease the antihypertensive activities of Bevantolol. Approved Paroxetine The serum concentration of Bevantolol can be increased when it is combined with Paroxetine. Approved, Investigational Parthenolide Parthenolide may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Pentobarbital The serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Perazine Perazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Pergolide Pergolide may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational, Vet Approved, Withdrawn Perphenazine Perphenazine may increase the hypotensive activities of Bevantolol. Approved Peruvoside Bevantolol may increase the bradycardic activities of Peruvoside. Experimental Phenobarbital The serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenylbutazone Phenylbutazone may decrease the antihypertensive activities of Bevantolol. Approved, Vet Approved Physostigmine Physostigmine may increase the bradycardic activities of Bevantolol. Approved, Investigational Pilocarpine The risk or severity of adverse effects can be increased when Bevantolol is combined with Pilocarpine. Approved, Investigational Pimecrolimus Pimecrolimus may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Pirfenidone Pirfenidone may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Piroxicam Piroxicam may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Pirprofen Pirprofen may decrease the antihypertensive activities of Bevantolol. Experimental Pranoprofen Pranoprofen may decrease the antihypertensive activities of Bevantolol. Experimental, Investigational Prazosin Bevantolol may increase the orthostatic hypotensive activities of Prazosin. Approved Primaquine The metabolism of Bevantolol can be decreased when combined with Primaquine. Approved Primidone The serum concentration of Bevantolol can be decreased when it is combined with Primidone. Approved, Vet Approved Prochlorperazine Prochlorperazine may increase the hypotensive activities of Bevantolol. Approved, Vet Approved Proglumetacin Proglumetacin may decrease the antihypertensive activities of Bevantolol. Experimental Promazine Promazine may increase the hypotensive activities of Bevantolol. Approved, Vet Approved Promethazine Promethazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Propacetamol Propacetamol may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Propafenone The serum concentration of Bevantolol can be increased when it is combined with Propafenone. Approved Propericiazine Propericiazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Propiopromazine Propiopromazine may increase the hypotensive activities of Bevantolol. Vet Approved Propyphenazone Propyphenazone may decrease the antihypertensive activities of Bevantolol. Experimental Proquazone Proquazone may decrease the antihypertensive activities of Bevantolol. Experimental Proscillaridin Bevantolol may increase the bradycardic activities of Proscillaridin. Experimental Pseudoephedrine Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved PTC299 PTC299 may decrease the antihypertensive activities of Bevantolol. Investigational Pyridostigmine Pyridostigmine may increase the bradycardic activities of Bevantolol. Approved, Investigational Racepinephrine Racepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved Regorafenib Regorafenib may increase the bradycardic activities of Bevantolol. Approved Remifentanil Remifentanil may increase the bradycardic activities of Bevantolol. Approved Reserpine Reserpine may increase the hypotensive activities of Bevantolol. Approved, Investigational Resveratrol Resveratrol may decrease the antihypertensive activities of Bevantolol. Approved, Experimental, Investigational Rifampicin The serum concentration of Bevantolol can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Bevantolol can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Bevantolol can be decreased when it is combined with Rifaximin. Approved, Investigational Risperidone Risperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Rivastigmine Bevantolol may increase the bradycardic activities of Rivastigmine. Approved, Investigational Rofecoxib Rofecoxib may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Withdrawn Ropinirole Ropinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Salicylamide Salicylamide may decrease the antihypertensive activities of Bevantolol. Approved Salicylic acid Salicylic acid may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Vet Approved Salsalate Salsalate may decrease the antihypertensive activities of Bevantolol. Approved Secobarbital The serum concentration of Bevantolol can be decreased when it is combined with Secobarbital. Approved, Vet Approved Semapimod Semapimod may decrease the antihypertensive activities of Bevantolol. Investigational Seratrodast Seratrodast may decrease the antihypertensive activities of Bevantolol. Approved Serrapeptase Serrapeptase may decrease the antihypertensive activities of Bevantolol. Investigational Sertraline The serum concentration of Bevantolol can be increased when it is combined with Sertraline. Approved Silodosin Bevantolol may increase the orthostatic hypotensive activities of Silodosin. Approved SRT501 SRT501 may decrease the antihypertensive activities of Bevantolol. Investigational Sufentanil Sufentanil may increase the bradycardic activities of Bevantolol. Approved, Investigational Sulfasalazine Sulfasalazine may decrease the antihypertensive activities of Bevantolol. Approved Sulindac Sulindac may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Suprofen Suprofen may decrease the antihypertensive activities of Bevantolol. Approved, Withdrawn Suxibuzone Suxibuzone may decrease the antihypertensive activities of Bevantolol. Experimental Tacrine Tacrine may increase the bradycardic activities of Bevantolol. Investigational, Withdrawn Tamsulosin Bevantolol may increase the orthostatic hypotensive activities of Tamsulosin. Approved, Investigational Tarenflurbil Tarenflurbil may decrease the antihypertensive activities of Bevantolol. Investigational Tenidap Tenidap may decrease the antihypertensive activities of Bevantolol. Experimental Tenoxicam Tenoxicam may decrease the antihypertensive activities of Bevantolol. Approved Tepoxalin Tepoxalin may decrease the antihypertensive activities of Bevantolol. Vet Approved Terazosin Bevantolol may increase the orthostatic hypotensive activities of Terazosin. Approved Teriflunomide Teriflunomide may decrease the antihypertensive activities of Bevantolol. Approved Thiamylal The serum concentration of Bevantolol can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Bevantolol. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Bevantolol. Withdrawn Thiopental The serum concentration of Bevantolol can be decreased when it is combined with Thiopental. Approved, Vet Approved Thioproperazine Thioproperazine may increase the hypotensive activities of Bevantolol. Approved Thioridazine Thioridazine may increase the hypotensive activities of Bevantolol. Approved, Withdrawn Tiaprofenic acid Tiaprofenic acid may decrease the antihypertensive activities of Bevantolol. Approved Tinoridine Tinoridine may decrease the antihypertensive activities of Bevantolol. Investigational Tizanidine Tizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Tolazamide Bevantolol may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Bevantolol may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid Tolfenamic Acid may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Tolmetin Tolmetin may decrease the antihypertensive activities of Bevantolol. Approved Tranilast Tranilast may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Tribenoside Tribenoside may decrease the antihypertensive activities of Bevantolol. Experimental Trichlorfon Trichlorfon may increase the bradycardic activities of Bevantolol. Vet Approved Trifluoperazine Trifluoperazine may increase the hypotensive activities of Bevantolol. Approved, Investigational Triflupromazine Triflupromazine may increase the hypotensive activities of Bevantolol. Approved, Vet Approved Trimazosin Bevantolol may increase the orthostatic hypotensive activities of Trimazosin. Experimental Triptolide Triptolide may decrease the antihypertensive activities of Bevantolol. Investigational Tubocurarine Tubocurarine may increase the bradycardic activities of Bevantolol. Approved Urapidil Bevantolol may increase the orthostatic hypotensive activities of Urapidil. Investigational Valdecoxib Valdecoxib may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Withdrawn Varenicline The risk or severity of adverse effects can be increased when Bevantolol is combined with Varenicline. Approved, Investigational Venlafaxine The serum concentration of Bevantolol can be increased when it is combined with Venlafaxine. Approved Verapamil Verapamil may increase the hypotensive activities of Bevantolol. Approved Xylazine Xylazine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Vet Approved Xylometazoline Xylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol. Approved, Investigational Zaltoprofen Zaltoprofen may decrease the antihypertensive activities of Bevantolol. Approved, Investigational Zileuton Zileuton may decrease the antihypertensive activities of Bevantolol. Approved, Investigational, Withdrawn Zimelidine The serum concentration of Bevantolol can be increased when it is combined with Zimelidine. Withdrawn Zomepirac Zomepirac may decrease the antihypertensive activities of Bevantolol. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Yutaka Nomura, "Process for preparation of bevantolol hydrochloride." U.S. Patent US5382689, issued December, 1974.
US5382689- General References
- Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
- External Links
- Human Metabolome Database
- HMDB0015409
- PubChem Compound
- 2372
- PubChem Substance
- 46506014
- ChemSpider
- 2282
- ChEBI
- 238698
- ChEMBL
- CHEMBL314010
- Therapeutic Targets Database
- DAP000897
- PharmGKB
- PA164743236
- Wikipedia
- Bevantolol
- ATC Codes
- C07AB06 — Bevantolol
- C07AB — Beta blocking agents, selective
- C07A — BETA BLOCKING AGENTS
- C07 — BETA BLOCKING AGENTS
- C — CARDIOVASCULAR SYSTEM
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 137-138 °C PhysProp logP 3.00 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.0137 mg/mL ALOGPS logP 2.83 ALOGPS logP 3.03 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 14.09 ChemAxon pKa (Strongest Basic) 9.31 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 59.95 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 98.54 m3·mol-1 ChemAxon Polarizability 39.75 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.8271 Blood Brain Barrier - 0.9297 Caco-2 permeable - 0.6012 P-glycoprotein substrate Substrate 0.8119 P-glycoprotein inhibitor I Inhibitor 0.625 P-glycoprotein inhibitor II Inhibitor 0.8061 Renal organic cation transporter Non-inhibitor 0.6935 CYP450 2C9 substrate Non-substrate 0.7741 CYP450 2D6 substrate Substrate 0.5792 CYP450 3A4 substrate Substrate 0.5727 CYP450 1A2 substrate Non-inhibitor 0.6261 CYP450 2C9 inhibitor Non-inhibitor 0.9068 CYP450 2D6 inhibitor Non-inhibitor 0.7311 CYP450 2C19 inhibitor Non-inhibitor 0.9218 CYP450 3A4 inhibitor Non-inhibitor 0.6133 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9339 Ames test Non AMES toxic 0.9124 Carcinogenicity Non-carcinogens 0.926 Biodegradation Not ready biodegradable 0.8696 Rat acute toxicity 2.0966 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.6187 hERG inhibition (predictor II) Inhibitor 0.8681
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Methoxybenzenes
- Direct Parent
- Dimethoxybenzenes
- Alternative Parents
- Phenethylamines / Phenoxy compounds / Anisoles / Toluenes / Aralkylamines / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds show 1 more
- Substituents
- Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Anisole / Phenol ether / Phenoxy compound / Alkyl aryl ether / Aralkylamine / Toluene / 1,2-aminoalcohol show 13 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- propanolamine (CHEBI:238698)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Receptor signaling protein activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
- Gene Name
- ADRB1
- Uniprot ID
- P08588
- Uniprot Name
- Beta-1 adrenergic receptor
- Molecular Weight
- 51322.1 Da
References
- Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. [PubMed:2568629]
- Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. [PubMed:2858236]
- Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. [PubMed:6148733]
- Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
- Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746]
Drug created on June 30, 2007 08:18 / Updated on March 02, 2018 02:10